Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism

Blood. 2005 Feb 15;105(4):1549-51. doi: 10.1182/blood-2004-08-3328. Epub 2004 Oct 14.

Abstract

The factor VII-activating protease (FSAP) variant Marburg I is known to attenuate the profibrinolytic system in vitro and was recently shown to be a significant predictor for the evolution and progression of carotid stenosis. The objective of this case-control study was to assess FSAP Marburg I's role in the occurrence of venous thromboembolism (VTE). The frequency of FSAP Marburg I was significantly increased in patients with a history of VTE (17 of 213 patients, 8.0%, P = .014) or idiopathic VTE (12 of 103 patients, 11.7%, P = .002) compared to healthy controls (5 of 213 controls, 2.3%). Logistic regression analysis confirmed FSAP Marburg I to be an independent risk factor for VTE (odds ratio, 3.5; 95% confidence interval [CI], 1.2-10.0) and idiopathic VTE (odds ratio, 6.2; 95% CI, 2.0-18.9).

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Female
  • Gene Frequency
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Prevalence
  • Risk Factors
  • Serine Endopeptidases / genetics*
  • Serine Endopeptidases / physiology
  • Thromboembolism / enzymology
  • Thromboembolism / epidemiology
  • Thromboembolism / genetics*
  • Venous Thrombosis / enzymology
  • Venous Thrombosis / epidemiology
  • Venous Thrombosis / genetics*

Substances

  • HABP2 protein, human
  • Serine Endopeptidases